ARTICLE | Distillery Therapeutics
Therapeutics: MLX interacting protein (MLXIP); thioredoxin interacting protein (TXNIP); arrestin domain containing 4 (ARRDC4)
September 15, 2016 7:00 AM UTC
Cell culture and mouse studies suggest inhibiting the MLXIP/TXNIP/ARRDC4 pathway could help treat obesity. In cultured human skeletal myotubes, siRNA targeting MLXIP or a MLXIP inhibitor tool compound...